Cediranib

CAS No. 288383-20-0

Cediranib( AZD2171 | AZD 2171 | AZD-2171 )

Catalog No. M13883 CAS No. 288383-20-0

A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 32 In Stock
5MG 51 In Stock
10MG 76 In Stock
25MG 124 In Stock
50MG 168 In Stock
100MG 240 In Stock
200MG 438 In Stock
500MG 704 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cediranib
  • Note
    Research use only, not for human use.
  • Brief Description
    A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.
  • Description
    A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively; also inhibits c-Kit and PDGFRβ with IC50 of 2 and 5 nM, >36-fold selectivity over PDGFR-α, >1000-fold over Flt-3 and EGFR; inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM in human umbilical vein endothelial cells; inhibits angiogenesis, neovascular survival and tumor growth in vivo. Ovarian Cancer Phase 3 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    AZD2171 | AZD 2171 | AZD-2171
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    c-Kit|PDGFRβ|VEGFR1/FLT1|VEGFR2/KDR|VEGFR3/FLT4
  • Research Area
    Cancer
  • Indication
    Ovarian Cancer

Chemical Information

  • CAS Number
    288383-20-0
  • Formula Weight
    450.5053
  • Molecular Formula
    C25H27FN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 49 mg/mL
  • SMILES
    COC1=C(OCCCN2CCCC2)C=C2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1
  • Chemical Name
    Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wedge SR, et al. Cancer Res. 2005 May 15;65(10):4389-400. 2. Denduluri N, et al. Clin Breast Cancer. 2005 Dec;6(5):460-3. 3. Batchelor TT, et al. Cancer Cell. 2007 Jan;11(1):83-95. 4. Cao C, et al. Cancer Res. 2006 Dec 1;66(23):11409-15.
molnova catalog
related products
  • AMPK-IN-3

    AMPK-IN-3 is a novel, selective and potent AMPK inhibitor with inhibitory effects on AMPK (α2), AMPK (α1) and KDR, with IC50 values of 60.7, 107 and 3820 nM, respectively.AMPK-IN-3 showed anticancer activity in K562 cells.

  • Tyrphostin AG1433

    Tyrphostin AG1433 is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM).

  • SU14813

    A broad-spectrum RTKs inhibitor with IC50 ranging from 2 to 50 nM for VEGFR-1, VEGFR-2, PDGFRs, KIT, FLT3, and CSF1R/FMS.